Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Jan;163(1):153-5.
doi: 10.1176/appi.ajp.163.1.153.

A double-blind, placebo-controlled study of memantine in the treatment of major depression

Carlos A Zarate Jr  1 , Jaskaran B Singh, Jorge A Quiroz, Georgette De Jesus, Kirk K Denicoff, David A Luckenbaugh, Husseini K Manji, Dennis S Charney
Affiliations
Randomized Controlled Trial

A double-blind, placebo-controlled study of memantine in the treatment of major depression

Carlos A Zarate Jr et al. Am J Psychiatry. 2006 Jan.

Abstract

Objective: This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans.

Method: In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS).

Results: The linear mixed models for total MADRS scores showed no treatment effect.

Conclusions: In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.

PubMed Disclaimer

Publication types

LinkOut - more resources